Recent advances and future prospects in choroideremia

Martin S Zinkernagel¹,² Robert E MacLaren³,⁴
¹Department of Ophthalmology, ²Department of Clinical Research, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland; ³Nuffield Laboratory of Ophthalmology, University of Oxford and Oxford Eye Hospital, Oxford University NHS Trust NIHR Biomedical Research Centre, Oxford, UK; ⁴Moorfields Eye Hospital NIHR Biomedical Research Centre, London, UK

Abstract: Choroideremia is a complex and rare disease that is frequently misdiagnosed due to its similar appearance to classic retinitis pigmentosa. Recent advances in genetic testing have identified specific genetic mutations in many retinal dystrophies, and the identification of the mutation of the CHM gene on the X chromosome 25 years ago has paved the way for gene replacement therapy with the first human trials now underway. This article reviews the epidemiological and pathological features of choroideremia and new prospects in imaging to monitor disease progression, as well as potential treatment approaches for choroideremia.

Keywords: choroideremia, gene replacement therapy, retinal imaging, clinical trials

Introduction
Choroideremia is an X-linked, recessive disease of the retina resulting in progressive degeneration of the retina, the retinal pigment epithelium (RPE), and the choroid. The prevalence of choroideremia is estimated to be approximately 1:50,000 in people of European descent.

The disease is characterized by the clinical appearance of atrophy of the choroid resulting in a characteristic pale color of the fundus, originating from the translucence of the white sclera (Figure 1). In males, the condition gradually advances and starts with night blindness and eventually results in progressive loss of peripheral vision and total blindness in the late stages, although some extreme peripheral field detection may remain. However, disease progression is relatively slow and the fovea is generally only affected in the end stages of the disease. Therefore, patients may retain good central visual function as late as 50–70 years old.

Although X-linked diseases preferentially occur in men (as they have only one X chromosome) choroideremia may also present in female carriers. Carrier females may show characteristic pigmentary changes of the fundus with patchy chorioretinal degeneration. This is due to the process of lyonization in which one copy of the X chromosome is silenced and therefore cells carrying the mutation are intermixed with cells expressing the normal X chromosome resulting in a mosaic pattern of the disease. Therefore, most female carriers are asymptomatic and maintain normal visual acuity. The characteristic fundus appearance and a family history consistent with X-linked disease are sufficient for the diagnosis of choroideremia. Other retinal dystrophies with similar fundus appearance can usually be ruled out by family history or laboratory testing. These include autosomal recessive gyrate atrophy which can usually be ruled out by family history and testing for hyperornithinemia, Oliver–McFarlane syndrome, a PNPLA6-related disorder and dominantly negative...
mutations in RPE65 or bifocal chorioretinal atrophy, and an autosomal dominant disease with a gene mutation on chromosome 6, 6–8

There are several reports on the histological changes in choroideremia – this is critically important for designing treatments, because it is essential to know which retinal cells are affected by the CHM gene deficiency and therefore need to be targeted by gene therapy vectors. In postmortem histological sections, independent degeneration of choriocapillaris, RPE, and neurosensory retina have been described. Furthermore, areas of relatively well-preserved retinal architecture were found adjacent to areas of severe degeneration, corresponding to the clinical fundus appearance. 9,10 Photoreceptor degeneration was less pronounced above preserved RPE, but occasionally photoreceptor loss was seen in areas with preserved RPE. 11 Within the affected areas, the retina was thinned due to thinning of outer segments of the photoreceptors and loss of nuclei within the outer nuclear layer. Subsequently, loss of nuclei within the inner nuclear layer was found as well. 11 In addition, there was profound rarefication of most vasculature and melanocytes within the choroid. There is some evidence that inflammation occurs within the retina in patients with choroideremia: a recent report has provided evidence of a mild T-lymphocytic infiltration within the choroid. 11 Furthermore, pigment filled macrophages have been identified in the subretinal space associated with rosette formation of the retina. 12 Whereas inflammation is not likely to play an active part in the pathogenesis of choroideremia, there seems to be a reactive inflammatory response in the areas of active disease as photoreceptor debris usually is phagocytized and removed by macrophages.13

Retinal imaging in choroideremia and implications for gene replacement therapy

In the last decade, advances in retinal imaging have led to an improved understanding of morphological changes occurring during the disease course of choroideremia. Optical coherence tomography (OCT) can be used to diagnose macular changes associated with choroideremia such as choroidal neovascularization, 14 cystoid macular edema, 15 epiretinal membrane formation, 16 outer retinal tubulations, 17 macular hole formation, 18 and macular hole complicated by retinal detachment. 19 Fundus autofluorescence shows a characteristic speckled pattern of low- and high-density fundus autofluorescence (Figure 2). 20 Increased lipofuscin accumulation originating from digestion of degenerating rods by RPE cells is thought to cause increased autofluorescence in choroideremia, whereas low density fluorescence reflects loss of the RPE layer whilst the choroid is still intact. This is corroborated by functional tests, showing an association of multifocal electroretinogram (mfERG) deterioration with major fundus autofluorescence changes. 20,21 Despite high resolution OCT and genetic characterization of choroideremia, the sequence of morphological changes leading to vision loss remains unknown. There are several theories on which retinal layers are primarily affected by choroideremia. Whereas some reports show that the RPE is the first layer to degenerate, followed by loss of photoreceptors, 22 others claim that the photoreceptor layer, 23 in particular the rods, 24 is primarily affected, followed by degeneration of the RPE and the choriocapillaris. The latter hypothesis is not however supported by the observations from patients with dominant RPE65 mutations who have a very similar choroidal atrophy appearance to CHM. Since the
Recent advances in choroideremia

**Figure 2** Multimodal imaging of a patient with choroideremia.  
**Notes:** (A) Fundus AF showing an island of hyperfluorescent intact retina (delineated by white arrows). (B) IR image with corresponding OCT scan line (the green line represents the OCT scan direction) and (C) OCT images of the same patient. In OCT, the marked atrophy of the retinal pigment epithelium with homogeneously increased reflectivity in OCT corresponds well with the borders seen in AF. There is a marked thinning of the outer nuclear layers and the choroida is virtually absent, both hallmarks of choroideremia.  
**Abbreviations:** AF, autofluorescence; OCT, optical coherence tomography; IR, infrared.

*RPE65* gene is known to be expressed only in the RPE and being dominantly negative, we assume it causes RPE cell death; this phenotype provides an alternative pathway for the choroidal atrophy being RPE-driven in both diseases. Conversely, if CHM were a disease primarily of rod photoreceptor loss, then we might expect it to appear similar to the other forms of rod-cone dystrophy (retinitis pigmentosa).

Cone loss at the fovea and smaller atrophic-appearing cones at the edge of degeneration have also been found using adaptive optics scanning laser ophthalmoscopy. Functional tests such as mfERG and microperimetry are already employed to monitor therapeutic responses after gene replacement therapy. Future developments in imaging of retinal dystrophies should aim at identifying risk factors and reliable markers for disease progression. Here, several imaging modalities such as OCT angiography or fluorescence lifetime imaging ophthalmoscopy may provide disease specific information. In a recent report using en face OCT angiography, it has been shown that choriocapillaris nonperfusion was more pronounced than the retinal nonperfusion in patients with choroideremia. The observed choriocapillaris nonperfusion is thought to follow the RPE loss and may therefore possibly represent a marker for disease progression and/or response to treatment. Fluorescence lifetime imaging ophthalmoscopy is a novel imaging modality able to quantify fluorescence lifetimes in the retina. In contrast to fundus autofluorescence, fluorescence lifetimes are influenced by metabolic changes within the retina. Therefore, this imaging modality may be valuable to identify areas at risk for disease progression in retinal dystrophies and may be a valuable tool to assess therapeutic responses. The exact sequel of structural changes occurring within the retina has received increasing interest in the last years in light of emerging therapies for retinal diseases.

**Genetics of choroideremia**
Choroideremia is caused by mutations in the *CHM* gene, located on the long arm of the X chromosome, encoding...
the 95 kDa protein Rab escort protein 1 (REP1). The REP1
gene is ubiquitously expressed and acts as an escort protein
of native regulators of intracellular trafficking. The deletions
in the CHM gene causing choroideremia were first described
in 1990.29,30 Mutations in the CHM gene have been identified
in European,31–35 Canadian,36 American,37 Japanese,38
and Chinese families.39 These mutations cause truncation
or absence of REP1, which plays an essential role in the
intracellular vesicular transport. REP1 is involved in lipid
modification of Rab proteins by binding newly synthesized,
unprenylated Rabs and presenting them to a catalytic Rab
geranylgeranyltransferase or farnesyltransferase subunit
for the geranylgeranyl transfer reaction.40 Furthermore, REP1
facilitates transport of prenylated Rabs to their specific desti-
nation membrane by binding to the hydrophobic prenylation
motifs at their C termini.41 Rab proteins are present in all cells
and so far more than 50 Rab proteins have been identified.42
Within the eye, many processes such as transport of proteins
within the photoreceptors or regulation of phagocytosis and
degradation of disc membranes shed from the outer seg-
ments of photoreceptors by RPE are reliant on Rab protein
function. Generally, loss of REP1 is compensated by Rab
escort protein 2, a protein that closely resembles REP1 and
is encoded by the X-linked retinog enzyme CHML (choroideremia-
like), which is located on chromosome 1.43 Most newly
synthesized Rabs bind to one of the two REP proteins and
therefore mutations in CHM generally do not lead to sys-
temic disease. A possible explanation for the eye restricted
phenotype is that some Rabs, such as Rab 27a which has a
key role within the retina,44 are preferentially prenylated by
REP1 or that REP2 prenylated Rab27a complexes may have
a lower affinity to geranylgeranyltransferase.45 Therefore,
the phenotype of choroideremia may be mainly caused by
a tissue specific inability of REP2 to compensate for the
function of REP1.

Review of recent developments in
therapies for choroideremia

The retina is unusually accessible in the evaluation of trials
of gene therapy. Not only can disease progression be imaged
in nearly histological detail using high resolution OCT, but
also there are several functional tests available to monitor
therapeutic responses. Furthermore, modern vitreoretinal
techniques allow for controlled and local delivery of gene
replacement products to the affected tissue. Extensive prelimi-
nary work in mouse and dog models of retinal degeneration
have shown that the use of adeno-associated vectors to deliver
gene replacement therapy in the retina is safe and may result
in stable and substantial restoration of the gene product and
functional improvement.46 Of the many different adenovirus (AAV)
subtypes, AAV2 has a reasonable affinity for primate photoreceptors and RPE,47 but has the advantage
over other serotypes in being well characterized in a number
of animal models. Therefore, AAV2 has been used as the vector
for gene replacement therapy in several gene therapy trials
for retinal dystrophies.48–51 Because the amount of genetic
material is limited by the packaging capacity of the vector,
the size of gene to be replaced is of critical relevance. The
limit for AAV vectors is estimated to be around 5 kb for single
stranded DNA.52 With a total size of approximately 1.9 kb,
the coding sequence of REP1 fits well within the packaging
limit of AAV2 with spare space for other regulatory elements,
such as the promoter and poly-A signal sequences.

Preclinical studies have shown the feasibility of REP1
replacement therapy using AAV2 in Chmnull/+ mice. In Chmnull/+ mice, selective ablation of Chm in photoreceptor cells or the
RPE results in independent degeneration of both of these
layers resembling the clinical phenotype of choroideremia.53
Using AAV2-REP1 delivered subretinally, a dose-dependent
improvement of retinal function was observed in Chmnull/+ mice. These findings served as proof of concept for future
clinical gene replacement therapies in humans.54

Retinal gene therapy in humans involves delivery of a
viral vector to the photoreceptors and the RPE. In order to
reach this tissue, a pars plana vitrectomy is necessary, fol-
lowed by a small retinotomy and subretinal injection of fluid
containing the vector. This procedure is highly complex
because it must be done without damaging the fovea in a
degenerate retina. The injection, to some extent, resembles
subretinal injection of recombinant tissue plasminogen acti-

tor for the treatment and displacement of subretinal hemor-
rhage, although in these cases the retina is already detached
and the visual acuity is severely compromised. In CHM,
the potential risks of subretinal gene therapy should not be
underestimated as the delivery of the vector entails detach-
ment of the fovea which may lead to reduction of contrast
sensitivity or even visual acuity. Furthermore, it is unknown
whether or not the gene product or the vector might cause an
immune reaction with potentially detrimental effects to the
retina in some individuals.

Recently, preliminary results of a Phase I–II clinical trial
assessing the effects of the AAV-REP1 vector in six patients
with choroideremia have been published.55 In this report,
gene therapy with AAV2-REP1 was shown to be safe with
a greater than 2- and 4-line improvement of visual acuity in
two patients. Furthermore, it was shown that the five patients
who received the full dose of AAV vector had improvements in mean retinal sensitivity. In this study, only patients with advanced disease with macular involvement were included. Four patients had near normal best corrected visual acuity at baseline and detachment of the fovea, which was required for gene replacement delivery, was shown to be well tolerated in these patients. Future prospects of gene replacement therapy in patients with choroideremia should target patients at an early disease stage when the retinal architecture and function are still intact. This has several implications for the clinician. Because there is now a potential therapy for patients with choroideremia and other retinal dystrophies, counseling of patients in clinics should include information on current results of gene replacement trials. Furthermore, genetic testing and molecular diagnosis of the DNA or messenger RNA causing retinal dystrophy should be used to support the clinical diagnosis. Even in the case of clinically confirmed choroideremia, genetic confirmation should be obtained in order to determine whether a patient is suitable for future gene replacement therapy trials. In addition, it is important to establish a database of patients with confirmed genetic mutations to inform patients of forthcoming gene replacement therapies and offer them the possibility of participating in future trials.

**Disclosure**

REM is a founder and director of NightstaRx Ltd, a choroideremia gene therapy company established by the University of Oxford and funded by the Wellcome Trust. MSZ reports no conflicts of interest in this work.

**References**